174 related articles for article (PubMed ID: 29936783)
1. Re-Expression of Bone Marrow Proteoglycan-2 by 5-Azacytidine is associated with STAT3 Inactivation and Sensitivity Response to Imatinib in Resistant CML Cells.
Al-Jamal HAN; Johan MF; Mat Jusoh SA; Ismail I; Wan Taib WR
Asian Pac J Cancer Prev; 2018 Jun; 19(6):1585-1590. PubMed ID: 29936783
[TBL] [Abstract][Full Text] [Related]
2. Silencing of suppressor of cytokine signaling-3 due to methylation results in phosphorylation of STAT3 in imatinib resistant BCR-ABL positive chronic myeloid leukemia cells.
Al-Jamal HA; Jusoh SA; Yong AC; Asan JM; Hassan R; Johan MF
Asian Pac J Cancer Prev; 2014; 15(11):4555-61. PubMed ID: 24969884
[TBL] [Abstract][Full Text] [Related]
3. Enhancing SHP-1 expression with 5-azacytidine may inhibit STAT3 activation and confer sensitivity in lestaurtinib (CEP-701)-resistant FLT3-ITD positive acute myeloid leukemia.
Al-Jamal HA; Mat Jusoh SA; Hassan R; Johan MF
BMC Cancer; 2015 Nov; 15():869. PubMed ID: 26547689
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of RPS27a contributes to enhanced chemoresistance of CML cells to imatinib by the transactivated STAT3.
Wang H; Xie B; Kong Y; Tao Y; Yang G; Gao M; Xu H; Zhan F; Shi J; Zhang Y; Wu X
Oncotarget; 2016 Apr; 7(14):18638-50. PubMed ID: 26942564
[TBL] [Abstract][Full Text] [Related]
5. Bone marrow microenvironment confers imatinib resistance to chronic myelogenous leukemia and oroxylin A reverses the resistance by suppressing Stat3 pathway.
Li X; Miao H; Zhang Y; Li W; Li Z; Zhou Y; Zhao L; Guo Q
Arch Toxicol; 2015 Jan; 89(1):121-36. PubMed ID: 24671465
[TBL] [Abstract][Full Text] [Related]
6. Targeting Hedgehog signaling pathway and autophagy overcomes drug resistance of BCR-ABL-positive chronic myeloid leukemia.
Zeng X; Zhao H; Li Y; Fan J; Sun Y; Wang S; Wang Z; Song P; Ju D
Autophagy; 2015; 11(2):355-72. PubMed ID: 25701353
[TBL] [Abstract][Full Text] [Related]
7. A molecular and biophysical comparison of macromolecular changes in imatinib-sensitive and imatinib-resistant K562 cells exposed to ponatinib.
Yandim MK; Ceylan C; Elmas E; Baran Y
Tumour Biol; 2016 Feb; 37(2):2365-78. PubMed ID: 26373734
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with imatinib mesylate against chronic myelogenous leukemia cell lines.
Xin P; Li C; Zheng Y; Peng Q; Xiao H; Huang Y; Zhu X
Drug Des Devel Ther; 2017; 11():1115-1126. PubMed ID: 28435223
[TBL] [Abstract][Full Text] [Related]
9. Nickel pyrithione induces apoptosis in chronic myeloid leukemia cells resistant to imatinib via both Bcr/Abl-dependent and Bcr/Abl-independent mechanisms.
Lan X; Zhao C; Chen X; Zhang P; Zang D; Wu J; Chen J; Long H; Yang L; Huang H; Carter BZ; Wang X; Shi X; Liu J
J Hematol Oncol; 2016 Nov; 9(1):129. PubMed ID: 27884201
[TBL] [Abstract][Full Text] [Related]
10. Cryptotanshinone suppresses key onco-proliferative and drug-resistant pathways of chronic myeloid leukemia by targeting STAT5 and STAT3 phosphorylation.
Dong B; Liang Z; Chen Z; Li B; Zheng L; Yang J; Zhou H; Qu L
Sci China Life Sci; 2018 Sep; 61(9):999-1009. PubMed ID: 30054832
[TBL] [Abstract][Full Text] [Related]
11. Cryptotanshinone enhances the efficacy of Bcr-Abl tyrosine kinase inhibitors via inhibiting STAT3 and eIF4E signalling pathways in chronic myeloid leukaemia.
Cheng R; Huang Y; Fang Y; Wang Q; Yan M; Ge Y
Pharm Biol; 2021 Dec; 59(1):893-903. PubMed ID: 34214017
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of STAT3-interacting protein 1 (STATIP1) promotes STAT3 transcriptional up-regulation and imatinib mesylate resistance in the chronic myeloid leukemia.
Mencalha AL; Corrêa S; Salles D; Du Rocher B; Santiago MF; Abdelhay E
BMC Cancer; 2014 Nov; 14():866. PubMed ID: 25417721
[TBL] [Abstract][Full Text] [Related]
13. Epigenetic down-regulation of BIM expression is associated with reduced optimal responses to imatinib treatment in chronic myeloid leukaemia.
San José-Eneriz E; Agirre X; Jiménez-Velasco A; Cordeu L; Martín V; Arqueros V; Gárate L; Fresquet V; Cervantes F; Martínez-Climent JA; Heiniger A; Torres A; Prósper F; Roman-Gomez J
Eur J Cancer; 2009 Jul; 45(10):1877-89. PubMed ID: 19403302
[TBL] [Abstract][Full Text] [Related]
14. The antiproliferation effect of berbamine on k562 resistant cells by inhibiting NF-kappaB pathway.
Wei YL; Liang Y; Xu L; Zhao XY
Anat Rec (Hoboken); 2009 Jul; 292(7):945-50. PubMed ID: 19548306
[TBL] [Abstract][Full Text] [Related]
15. [Growth inhibition and differentiation of imatinib-resistant chronic myeloid leukemia cell induced by cell differentiation agent in vitro].
Wang XD; Qiu L; Lu RZ; Chen LJ; Zhan ZM; Han BH; Zhang BL; Ma J
Zhonghua Yi Xue Za Zhi; 2007 Dec; 87(48):3399-405. PubMed ID: 18476538
[TBL] [Abstract][Full Text] [Related]
16. A novel tubulin polymerization inhibitor, MPT0B206, downregulates Bcr-Abl expression and induces apoptosis in imatinib-sensitive and imatinib-resistant CML cells.
Chen CW; Lee YL; Liou JP; Liu YH; Liu CW; Chen TY; Huang HM
Apoptosis; 2016 Sep; 21(9):1008-18. PubMed ID: 27344662
[TBL] [Abstract][Full Text] [Related]
17. AKR1C3 decreased CML sensitivity to Imatinib in bone marrow microenvironment via dysregulation of miR-379-5p.
Pan D; Yang W; Zeng Y; Li W; Wang K; Zhao L; Li J; Ye Y; Guo Q
Cell Signal; 2021 Aug; 84():110038. PubMed ID: 33984486
[TBL] [Abstract][Full Text] [Related]
18. [Inhibitory effect and mechanism of platycodin D combined with imatinib on K562/R].
Dai Q; Ge YQ
Zhongguo Zhong Yao Za Zhi; 2018 Jan; 43(2):385-389. PubMed ID: 29552859
[TBL] [Abstract][Full Text] [Related]
19. Use of deferasirox, an iron chelator, to overcome imatinib resistance of chronic myeloid leukemia cells.
Kim DS; Na YJ; Kang MH; Yoon SY; Choi CW
Korean J Intern Med; 2016 Mar; 31(2):357-66. PubMed ID: 26874514
[TBL] [Abstract][Full Text] [Related]
20. miR-101 sensitizes K562 cell line to imatinib through Jak2 downregulation and inhibition of NF-κB target genes.
Farhadi E; Zaker F; Safa M; Rezvani MR
Tumour Biol; 2016 Oct; 37(10):14117-14128. PubMed ID: 27517565
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
